Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Operating Leases (2020 - 2025)

Mirum Pharmaceuticals has reported Operating Leases over the past 6 years, most recently at $7.5 million for Q4 2025.

  • Quarterly results put Operating Leases at $7.5 million for Q4 2025, down 5.72% from a year ago — trailing twelve months through Dec 2025 was $7.5 million (down 5.72% YoY), and the annual figure for FY2025 was $7.5 million, down 5.72%.
  • Operating Leases for Q4 2025 was $7.5 million at Mirum Pharmaceuticals, up from $7.4 million in the prior quarter.
  • Over the last five years, Operating Leases for MIRM hit a ceiling of $10.0 million in Q2 2025 and a floor of $328000.0 in Q1 2024.
  • Median Operating Leases over the past 5 years was $2.0 million (2021), compared with a mean of $3.8 million.
  • Biggest five-year swings in Operating Leases: crashed 68.91% in 2024 and later soared 2035.06% in 2025.
  • Mirum Pharmaceuticals' Operating Leases stood at $1.9 million in 2021, then crashed by 33.95% to $1.3 million in 2022, then tumbled by 50.91% to $617000.0 in 2023, then soared by 1192.06% to $8.0 million in 2024, then dropped by 5.72% to $7.5 million in 2025.
  • The last three reported values for Operating Leases were $7.5 million (Q4 2025), $7.4 million (Q3 2025), and $10.0 million (Q2 2025) per Business Quant data.